262 related articles for article (PubMed ID: 20727764)
21. Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes.
Mohme M; Schliffke S; Maire CL; Rünger A; Glau L; Mende KC; Matschke J; Gehbauer C; Akyüz N; Zapf S; Holz M; Schaper M; Martens T; Schmidt NO; Peine S; Westphal M; Binder M; Tolosa E; Lamszus K
Clin Cancer Res; 2018 Sep; 24(17):4187-4200. PubMed ID: 29444930
[No Abstract] [Full Text] [Related]
22. Analysis of immunobiologic markers in primary and recurrent glioblastoma.
Rahman M; Kresak J; Yang C; Huang J; Hiser W; Kubilis P; Mitchell D
J Neurooncol; 2018 Apr; 137(2):249-257. PubMed ID: 29302887
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients.
Migliorini D; Dutoit V; Allard M; Grandjean Hallez N; Marinari E; Widmer V; Philippin G; Corlazzoli F; Gustave R; Kreutzfeldt M; Blazek N; Wasem J; Hottinger A; Koka A; Momjian S; Lobrinus A; Merkler D; Vargas MI; Walker PR; Patrikidou A; Dietrich PY
Neuro Oncol; 2019 Jul; 21(7):923-933. PubMed ID: 30753611
[TBL] [Abstract][Full Text] [Related]
24. Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses.
Alayo QA; Ito H; Passaro C; Zdioruk M; Mahmoud AB; Grauwet K; Zhang X; Lawler SE; Reardon DA; Goins WF; Fernandez S; Chiocca EA; Nakashima H
Sci Rep; 2020 Mar; 10(1):5095. PubMed ID: 32198420
[TBL] [Abstract][Full Text] [Related]
25. Tapasin and human leukocyte antigen class I dysregulation correlates with survival in glioblastoma multiforme.
Thuring C; Geironson L; Paulsson K
Anticancer Agents Med Chem; 2014; 14(8):1101-9. PubMed ID: 25175688
[TBL] [Abstract][Full Text] [Related]
26. T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.
Woroniecka K; Chongsathidkiet P; Rhodin K; Kemeny H; Dechant C; Farber SH; Elsamadicy AA; Cui X; Koyama S; Jackson C; Hansen LJ; Johanns TM; Sanchez-Perez L; Chandramohan V; Yu YA; Bigner DD; Giles A; Healy P; Dranoff G; Weinhold KJ; Dunn GP; Fecci PE
Clin Cancer Res; 2018 Sep; 24(17):4175-4186. PubMed ID: 29437767
[No Abstract] [Full Text] [Related]
27. Long-term survival with glioblastoma multiforme.
Krex D; Klink B; Hartmann C; von Deimling A; Pietsch T; Simon M; Sabel M; Steinbach JP; Heese O; Reifenberger G; Weller M; Schackert G;
Brain; 2007 Oct; 130(Pt 10):2596-606. PubMed ID: 17785346
[TBL] [Abstract][Full Text] [Related]
28. Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.
Miyazaki T; Ishikawa E; Matsuda M; Akutsu H; Osuka S; Sakamoto N; Takano S; Yamamoto T; Tsuboi K; Matsumura A
J Neurooncol; 2017 Jun; 133(2):277-285. PubMed ID: 28447277
[TBL] [Abstract][Full Text] [Related]
29. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas.
Okada H; Lieberman FS; Walter KA; Lunsford LD; Kondziolka DS; Bejjani GK; Hamilton RL; Torres-Trejo A; Kalinski P; Cai Q; Mabold JL; Edington HD; Butterfield LH; Whiteside TL; Potter DM; Schold SC; Pollack IF
J Transl Med; 2007 Dec; 5():67. PubMed ID: 18093335
[TBL] [Abstract][Full Text] [Related]
30. Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness.
Lemke D; Pfenning PN; Sahm F; Klein AC; Kempf T; Warnken U; Schnölzer M; Tudoran R; Weller M; Platten M; Wick W
Clin Cancer Res; 2012 Jan; 18(1):105-17. PubMed ID: 22080438
[TBL] [Abstract][Full Text] [Related]
31. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination.
Wheeler CJ; Das A; Liu G; Yu JS; Black KL
Clin Cancer Res; 2004 Aug; 10(16):5316-26. PubMed ID: 15328167
[TBL] [Abstract][Full Text] [Related]
32. Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients.
Han SJ; Yang I; Otero JJ; Ahn BJ; Tihan T; McDermott MW; Berger MS; Chang SM; Parsa AT
J Neurosurg; 2010 May; 112(5):990-6. PubMed ID: 19817543
[TBL] [Abstract][Full Text] [Related]
33. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection?
Li YM; Suki D; Hess K; Sawaya R
J Neurosurg; 2016 Apr; 124(4):977-88. PubMed ID: 26495941
[TBL] [Abstract][Full Text] [Related]
34. IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma.
Liu Y; Song C; Shen F; Zhang J; Song SW
PLoS One; 2019; 14(9):e0222999. PubMed ID: 31560714
[TBL] [Abstract][Full Text] [Related]
35. Exosomes from murine-derived GL26 cells promote glioblastoma tumor growth by reducing number and function of CD8+T cells.
Liu ZM; Wang YB; Yuan XH
Asian Pac J Cancer Prev; 2013; 14(1):309-14. PubMed ID: 23534743
[TBL] [Abstract][Full Text] [Related]
36. Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma.
Fu W; Wang W; Li H; Jiao Y; Huo R; Yan Z; Wang J; Wang S; Wang J; Chen D; Cao Y; Zhao J
Front Immunol; 2020; 11():835. PubMed ID: 32457755
[TBL] [Abstract][Full Text] [Related]
37. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
38. Explicating the Pivotal Pathogenic, Diagnostic, and Therapeutic Biomarker Potentials of Myeloid-Derived Suppressor Cells in Glioblastoma.
Richard SA
Dis Markers; 2020; 2020():8844313. PubMed ID: 33204365
[TBL] [Abstract][Full Text] [Related]
39. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
[TBL] [Abstract][Full Text] [Related]
40. Local Targeting of NAD
Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]